Parkinson disease: PD biomarkers-use of α-synuclein reaches new levels
- PMID: 21556033
- PMCID: PMC4043344
- DOI: 10.1038/nrneurol.2011.66
Parkinson disease: PD biomarkers-use of α-synuclein reaches new levels
Abstract
Biomarker development is important to the therapeutic imperative for neurodegenerative diseases, as biomarkers hold transformative promise for the design and conduct of clinical trials and, ultimately, for medical management of these diseases. Some of this promise is now being realized in Alzheimer disease, and progress in Parkinson disease is accelerating.
Conflict of interest statement
Competing interests: The author declares no competing interests.
Comment on
-
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Lancet Neurol. 2011. PMID: 21317042
References
-
- Mollenhauer B, et al. α-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10:230–240. - PubMed
-
- Fagan AM, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol. 2006;59:512–519. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
